US 12,274,689 B2
Compound for the management of feline diabetes
Michael Hadd, San Jose, CA (US); Albert Collinson, Berlin, MA (US); and Brian Seed, Boston, MA (US)
Assigned to IncreVet, Inc., Framingham, MA (US)
Filed by INCREVET, INC., Boston, MA (US)
Filed on Mar. 13, 2020, as Appl. No. 16/818,026.
Claims priority of provisional application 62/818,589, filed on Mar. 14, 2019.
Prior Publication US 2020/0289457 A1, Sep. 17, 2020
Int. Cl. A61K 31/351 (2006.01); A61P 3/10 (2006.01)
CPC A61K 31/351 (2013.01) [A61P 3/10 (2018.01)] 8 Claims
 
1. A method of managing diabetes in a cat in need thereof, said method comprising administering to the cat in need thereof a total daily dosage comprising about 5 to 50 mg of a pharmaceutically acceptable form of Compound 1,

OG Complex Work Unit Chemistry
wherein administration of said total daily dosage of Compound 1 reduces hyperglycemia-associated clinical signs comprising (a) polydipsia, (b) polyphagia, (c) polyuria, and (d) weight loss, and wherein the pharmaceutically acceptable form of Compound 1 is a crystalline form of Compound 1 characterized by Raman spectra including peaks at about 353, 688 and 825 cm−1.